Novavax Inc. (NASDAQ: NVAX) said Monday it received a crucial status for its Covid-19 vaccine candidate as the pandemic drags on and coronavirus cases once again soar across the country.
The Gaithersburg company has earned fast-track designation from the Food and Drug Administration for NVX-CoV2373, a coronavirus vaccine candidate in late-stage development. It means the biotech can submit parts of its application on a rolling basis for a speedier review by the agency, and gives Novavax more direct and frequent access to the FDA.
{iframe}https://www.bizjournals.com/washington/news/2020/11/09/novavax-secures-fast-track-status-from-fda-in-covi.html?ana=e_ae_prem&j=90536949&t=Afternoon&mkt_tok=eyJpIjoiWmpKak1XTTRORGRpTTJNMyIsInQiOiJUaitocE1Jd0xnYUVtUjJoNnozZ3hCVFF0OFhQSU51bnkxSzN5QityZkNvVXp0Zzh1VUx0bHlvT1NIQlc4YStnR09ub1o0Wk1xMHc3blZMR2hMVkdGenJvaXlGQmYwd1o5aXFmcGpjU2pNYUZ0Vmg4QmZNMmtkRW5pVFwvZjNQb2kifQ%3D%3D{/iframe}